Abstract
Background
Multiple sclerosis has a variable disease course. The contribution of modifiable lifestyle factors to disease course has not been well studied, although one cohort has reported that smoking is associated with conversion to secondary progressive MS course and another that smoking is not.
Methods
We conducted a prospective cohort study of people with MS in Southern Tasmania from 2002 to 2004 with 78 % (203/259) of eligible participating and 198 with one or more reviews and confirmed MS. The cohort had a high retention rate (90 % (183/203)). The median follow- up time was 909 days. Smoking data were collected at baseline and six-monthly reviews. Clinical disability assessments were conducted annually in conjunction with a real time clinical notification system for relapses. A repeated measures analysis and other statistical methods were used.
Results
Cumulative pack-years (p-y) smoked after cohort entry was associated with an increase in longitudinal MSSS (p < 0.001). Relative to the 0 pack years (p-y) category (in the year prior to the MSSS measure) those in the 0 to 1 p-y category had an adjusted mean difference in MSSS of 0.34 (95 % CI 0.28, 0.66); those in the 1 to 2 p-y category had a 0.41 (95 % CI −0.03, 0.85) increase; and those in the 2 or more p-y category had a 0.99 (95 % CI 0.41, 1.58) increase in MSSS. Similar results were found using a variety of statistical approaches or EDSS as a clinical outcome. Smoking during the cohort period was not associated with relapse (cumulative pack years smoked after cohort entry, HR 0.94 (0.69, 1.26) per pack year).
Conclusion
A better understanding of the mechanisms underlying smoking and multiple sclerosis, particularly progressive forms of the disease, may provide new insights for the eventual goal of better treatment and prevention of multiple sclerosis.
Abbreviations
- 25(OH) D:
-
25 hydroxy vitamin D
- AOR:
-
adjusted odds ratio
- CI:
-
confidence interval
- DNA:
-
deoxyribonucleic acid
- EDSS:
-
expanded disability status scale
- HR:
-
hazard ratio
- OR:
-
odds ratio
- MRI:
-
magnetic resonance imaging
- MS:
-
multiple sclerosis
- MSSS:
-
multiple sclerosis severity score
- PP:
-
primary progressive course
- p-y:
-
pack-years
- RR:
-
relapsing remitting course
- SP:
-
secondary progressive course
- UVR:
-
ultraviolet radiation
References
Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H (2005) Cigarette smoking and the progression of multiple sclerosis. Brain 128(Pt 6): 1461–1465
Koch M, van Harten A, Uyttenboogaart M, De Keyser J (2007) Cigarette smoking and progression in multiple sclerosis. Neurology 69(15):1515–1520
Emre M, de Decker C (1987) Nicotine and CNS. Neurology 37(12):1887–1888
Emre M, de Decker C (1992) Effects of cigarette smoking on motor functions in patients with multiple sclerosis. Arch Neurol 49(12):1243–1247
Pekmezovic T, Drulovic J, Milenkovic M, Jarebinski M, Stojsavljevic N, Mesaros S, et al. (2006) Lifestyle factors and multiple sclerosis: A case-control study in Belgrade. Neuroepidemiology 27(4):212–216
Ghadirian P, Dadgostar B, Azani R, Maisonneuve P (2001) A case control study of the association between socio-demographic, lifestyle and medical history factors and multiple sclerosis. Can J Public Health 92:281–285
Zorzon M, Zivadinov R, Nasuelli D, Dolfini P, Bosco A, Bratina A, et al. (2003) Risk factors for multiple sclerosis: a case-control study. Neurol Sci 24:242–247
Riise T, Nortvedt MW, Ascherio A (2003) Smoking is a risk factor for multiple sclerosis. Neurology 61(8):1122–1124
Hernan MA, Olek MJ, Ascherio A (2001) Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 154(1):69–74
van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, et al. (2003) Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ (Clinical research ed.) 327(7410):316
White V, Hill D, Siapush M, Bobevsky I (2003) How has the prevalence of cigarette smoking changed among Australian adults? Trends in smoking prevalence between 1980 and 2001. Tobacco Control 12(Suppl II):ii67–ii74
Laaksonen M, Luoto R, Helakorpi S, Uutela A (2002) Associations between Health-Related Behaviors: A 7-Year Follow-up of Adults. Prev Med 34(2):162–170
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127
van der Mei IA, Blizzard L, Ponsonby AL, Dwyer T (2006) Validity and reliability of adult recall of past sun exposure in a case-control study of multiple sclerosis. Cancer Epidemiol Biomarkers Prev 15(8):1538–1544
Dwyer T, Muller HK, Blizzard L, Ashbolt R, Phillips G (1998) The use of spectrophotometry to estimate melanin density in Caucasians. Cancer Epidemiol Biomarkers Prev 7(3):203–206
Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. (2005) Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 12; 64(7):1144–1151
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 352(9139):1498–1504
Goldstein H (2003) Multilevel Statistical Models 3rd ed. London: Hodder Arnold
Petzold A, Eikelenboom MI, Keir G, et al. (2006) The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers. Mult Scler 12(3):325–328
Kleinbaum DG, Klein M (2005) Survival Analysis: a self-learning text. 2nd Ed. New York: Springer, pp 331, 390
Perneger TV (1998) What’s wrong with Bonferroni adjustments. BMJ 316(7139):1236–1238
Hawkes CH (2007) Smoking is a risk factor for multiple sclerosis: a metanalysis. Multiple sclerosis (Houndmills, Basingstoke, England) 13(5):610–615
Costenbader KH, Karlson EW (2006) Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus 15(11):737–745
Charil A, Filippi M (2007) Inflammatory demyelination and neurodegeneration in early multiple sclerosis. J Neurol Sci 259(1–2):7–15
Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46(3):296–304
Inglese M, Benedetti B, Filippi M (2005) The relation between MRI measures of inflammation and neurodegeneration in multiple sclerosis. J Neurol Sci 233(1–2):15–29
Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A, et al. (2003) Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126(Pt 2):433–437
Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125 (Pt 10):2202–2212
Inglese M, Mancardi GL, Pagani E, Rocca MA, Murialdo A, Saccardi R, et al. (2004) Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry 75(4):643–644
Trapp BD, Bo L, Mork S, Chang A (1999) Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 98(1):49–56
Smith KJ, Kapoor R, Hall SM, Davies M (2001) Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 49(4):470–476
Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ (2003) Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 53(2):174–180
Suemaru K, Kawasaki H, Gomita Y, Tanizaki Y (1997) Involvement of nitric oxide in development of tailtremor induced by repeated nicotine administration in rats. Eur J Pharmacol 335(2–3):139–143
Lee TJ, Zhang W, Sarwinski S (2000) Presynaptic beta(2)-adrenoceptors mediate nicotine-induced NOergic neurogenic dilation in porcine basilar arteries. Am J Physiol 279(2):H808–H816
Tonnessen BH, Severson SR, Hurt RD, Miller VM (2000) Modulation of nitric-oxide synthase by nicotine. J Pharmacol Exp Therapeutics 295(2): 601–606
Jack C, Antel J, Bruck W, Kuhlmann T (2007) Contrasting potential of nitric oxide and peroxynitrite to mediate oligodendrocyte injury in multiple sclerosis. Glia 55(9):926–934
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pittas, F., Ponsonby, AL., van der Mei, I.A.F. et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol 256, 577–585 (2009). https://doi.org/10.1007/s00415-009-0120-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-009-0120-2